Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-030849
Filing Date
2025-03-03
Accepted
2025-03-03 16:10:24
Documents
82
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K annx-20241231.htm   iXBRL 10-K 3092325
2 EX-10.10 annx-ex10_10.htm EX-10.10 29580
3 EX-19.1 annx-ex19_1.htm EX-19.1 173224
4 EX-23.1 annx-ex23_1.htm EX-23.1 3441
5 EX-31.1 annx-ex31_1.htm EX-31.1 18740
6 EX-31.2 annx-ex31_2.htm EX-31.2 18762
7 EX-32.1 annx-ex32_1.htm EX-32.1 16644
8 GRAPHIC img136305557_0.jpg GRAPHIC 343596
9 GRAPHIC img136305557_1.jpg GRAPHIC 29242
10 GRAPHIC img136305557_2.jpg GRAPHIC 111404
11 GRAPHIC img136305557_3.jpg GRAPHIC 109033
12 GRAPHIC img136305557_4.jpg GRAPHIC 642061
  Complete submission text file 0000950170-25-030849.txt   13839809

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT annx-20241231.xsd EX-101.SCH 1280464
84 EXTRACTED XBRL INSTANCE DOCUMENT annx-20241231_htm.xml XML 1737844
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39402 | Film No.: 25697978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)